6568 — KNC Laboratories Co Balance Sheet
0.000.00%
- ¥9bn
- ¥9bn
- ¥8bn
- 40
- 74
- 74
- 72
Annual balance sheet for KNC Laboratories Co, fiscal year end - March 31st, JPY millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | Yuho | Yuho | Yuho | Yuho | Yuho |
| Standards: | JAS | JAS | JAS | JAS | JAS |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 1,963 | 1,974 | 2,297 | 3,312 | 2,386 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 1,142 | 2,518 | 2,791 | 2,626 | 2,408 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 5,137 | 6,347 | 7,459 | 8,559 | 7,475 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 6,961 | 6,909 | 7,200 | 8,475 | 11,147 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 12,781 | 13,952 | 15,405 | 18,622 | 20,152 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 1,287 | 2,047 | 2,728 | 2,969 | 2,269 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 2,660 | 3,377 | 3,659 | 5,535 | 6,632 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Unrealized Gain / Loss | |||||
| Other Equity | |||||
| Total Equity | 10,121 | 10,575 | 11,745 | 13,087 | 13,520 |
| Total Liabilities & Shareholders' Equity | 12,781 | 13,952 | 15,405 | 18,622 | 20,152 |
| Total Common Shares Outstanding |